A novel HSV-1 virus, JS1/34.5-/47- purges contaminating breast cancer cells from bone marrow

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6853-6862

  Hu, Jennifer C ^a   Booth, Matthew J ^b   Tripuraneni, Gopichand ^a   Davies, Derek ^c   Zaidi, Syed A A ^a   De Bella, Manuela Tamburo ^a   Slade, Martin J ^a   Marley, Stephen B ^a   Gordon, Myrtle Y A ^a   Coffin, Robert S ^b,d   Coombes, R Charles ^a   Kamalati, Tahereh ^a,e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^d BioVex Ltd   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; VIRUS ONCOLYSATE;

ARTICLE; BONE MARROW; BREAST CANCER; CANCER CELL; CELL KILLING; CELL PROLIFERATION; COLONY FORMATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY; ELECTRON MICROSCOPY; HERPES SIMPLEX VIRUS 1; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

ADENOCARCINOMA; BONE MARROW; BONE MARROW CELLS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; HUMANS; KERATIN-19; MAMMARY GLANDS, HUMAN; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TUMOR MARKERS, BIOLOGICAL;

EID: 33845303948     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1228     Document Type: Article

References (45)

1. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with haematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7-11.
2. Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005;366:1935-44.
3. Papadopoulos KP, Noguera-Irizarry W, Wiebe L, et al. Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Bone Marrow Transplant 2005;36:491-7.
4. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
5. Bouabdallah R, Coso D, Costello R, et al. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single centre. Bone Marrow Transplant 2000;25:35-40.
6. Weinstein JL, Katzenenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-92.
7. El-Helw L, Coleman RE. Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours. Cancer Treat Rev 2005;31:197-209.
8. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73.
9. Muller V, Stahmann N, Riethdorf S, et al. Circulating tumour cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferate activity. Clin Cancer Res 2005;15:3678-85.
10. Sharp JG, Kessinger A, Mann S, et al. Outcome of high -dose therapy and autologus transplantation in non-Hodgkin's lymphoma based on the presence of tumour in the marrow or infused haematopoietic harvest. J Clin Oncol 1996;14:214-9.
11. Muller V, Pantel K. BM Micrometastases and circulating tumour cells in breast cancer patients: where have we been, where are we now and where does the future lie? Cytotherapy 2005;7:478-82.
12. Wieswang G, Borgen E, Schirmer C, et al. Comparison of the clinical significance of occult tumour cells in blood and bone marrow in breast cancer. Int J Cancer 2006;118:2013-19.
13. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumours can return a multiplicity of tumourogenic cells. Blood 1994;84:380-3.
14. Franklin WA, Shpall EJ, Archer P et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high-dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 1996;41:1-13.
15. Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28-36.
16. + hematopoietic progenitor cells with recombinant toxins. Blood 1998;91:1820-7.
17. Woelfle U, Breit E, Zafrakas K, et al. Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods 2005;300:136-45.
18. Wu A, Mazumder A, Martuza RL, et al. Biological purging of breast cancer cells using an attenuated replication competent herpes simplex virus in human haematopoietic stem cell transplantation. Cancer Res 2001;61:3009-15.
19. Seth P, Brinkmann U, Schwartz G, et al. Adenovirus-mediated gene transfer to human breast tumour cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res 1996;56:1346-51.
20. Shpall EJ, Jones RB, Bast RC, Jr., et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991;9:85-93.
21. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073-90.
22. Mapara MY, Korner IJ, Hildebrandt M, et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997;89:337-44.
23. + cell transplantation in children with neuroblastoma. Med Pediatr Oncol 2000;35:1-7.
24. Aghi M, Martuza RL. Oncolytic viral therapies: the clinical experience. Oncogene 2005;24:7802-16.
25. Andreansky SS, He B, Gillespe GY, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumours. Proc Natl Acad Sci U S A 1996;93:11313-18.
26. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303.
27. Kothari MS, Ali S, Buluwela L, et al. Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. Br J Cancer 2003;88:1071-6.
28. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
29. Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999;17:870-9.
30. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994;12:475-82.
31. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bohe marrow transplantation. J Clin Oncol 1996;14:1868-76.
32. Vannucchi AM, Bosi A, Glinz S, et al. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. Br J Haematol 1998;103:610-7.
33. Ikeda N, Miyoshi Y, Motomura K, Inaji H, Koyama H, Noguchi S. Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA. Jpn J Cancer Res 2000;91:918-24.
34. Aihara T, Noguchi S, Ishikawa O, et al. Detection of pancreatic and gastric cancer cells in peripheral and portal blood by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. Int J Cancer 1997;72:408-11.
35. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998;16:2632-40.
36. Novaes M, Bendit I, Garicochea B, del Giglio A. Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol 1997;50:209-11.
37. Lopez-Guerrero JA, Bolufer-Gilabert P, Sanz-Alonso M, et al. Minimal detected by a reverse transcription PCR method (RT-PCR). Clin Chim Acta 1997;263:105-16.
38. De Rosa L, Lalle M, Pandolfi A, Ruscio C, Amodeo R. Autologus bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission. Ann Hematol 2002;81:575-81.
39. Wagner LM, Guichard SM, Burger RA, et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: Preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002;62:5001-7.
40. Huang W, Tan W, Zhong Q, Schwarzenberger P. Development of a gene therapy based bone marrow purging system for leukemias. Cancer Gene Ther 2005;12:873-83.
41. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001;75:5189-96.
42. Taneja S, MacGregor J, Markus S, Ha S, Mohr I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A 2001;98:8804-8.
43. Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 2004;11:643-64.
44. Varghese A, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002;9:967-78.
45. Mansi JL, Easton D, Berger U, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years follow-up. Eur J Cancer 1991;27:1552-5.